Evidence map›Paper›PMID 31838735›Full record

ArticleInvestigational new drugs2020

Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells.

Mona Oliveira, Lourenço Luis Botelho de Santana, José Claudio Serafim, Airam Oliveira Santos, Michelle Pereira Quintino, José Tiago Menezes Correia, Fabiano Damasceno, José Ricardo Sabino, Thiago Rubens Cardim Pires, Paulo Lucas Cerqueira Coelho and 4 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Mona OliveiraDepartamento de Biofunção/Bioquímica, Laboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Salvador, BA 40.110-100, Brazil.
Lourenço Luis Botelho de SantanaInstituto de Química, Universidade Federal da Bahia, Campus de Ondina, Salvador, BA 40170-115, Brazil.
José Claudio SerafimInstituto de Química, Universidade Federal da Bahia, Campus de Ondina, Salvador, BA 40170-115, Brazil.
Airam Oliveira SantosInstituto de Química, Universidade Federal da Bahia, Campus de Ondina, Salvador, BA 40170-115, Brazil.
Michelle Pereira QuintinoInstituto de Química, Universidade Federal da Bahia, Campus de Ondina, Salvador, BA 40170-115, Brazil.
José Tiago Menezes CorreiaInstituto de Química, Universidade Federal da Bahia, Campus de Ondina, Salvador, BA 40170-115, Brazil.
Fabiano DamascenoInstituto de Química, Universidade Federal da Bahia, Campus de Ondina, Salvador, BA 40170-115, Brazil.
José Ricardo SabinoInstituto de Física, Universidade Federal de Goiás, CP 131, Goiânia, GO 74.001-970, Brazil.
Thiago Rubens Cardim PiresDepartamento de Biofunção/Bioquímica, Laboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Salvador, BA 40.110-100, Brazil.
Paulo Lucas Cerqueira CoelhoDepartamento de Biofunção/Bioquímica, Laboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Salvador, BA 40.110-100, Brazil.
Giselle Pinto de Faria LopesDepartamento de Biofunção/Bioquímica, Laboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Salvador, BA 40.110-100, Brazil.
Henning UlrichDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes, 748, Butantã, São Paulo, SP 05.508-000, Brazil.
Silvia Lima CostaDepartamento de Biofunção/Bioquímica, Laboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Salvador, BA 40.110-100, Brazil. costasl@ufba.br.ORCID http://orcid.org/0000-0002-8975-3871
Silvio CunhaInstituto de Química, Universidade Federal da Bahia, Campus de Ondina, Salvador, BA 40170-115, Brazil. silviodc@ufba.br.
Universidade Federal da Bahia · BRInstituto de Estudos do Mar Almirante Paulo Moreira · BRUniversidade de São Paulo · BRUniversidade Federal de Goiás · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Twelve multi-functional pyrrolizidinones, indolizidinones and pyrroliazepinones were prepared from formal aza-[3 + 2] and aza-[3 + 3] cycloadditions of five- to seven-membered heterocyclic enaminones as diverse ambident electrophiles. The antitumor activity of these alkaloid-like compounds was investigated through an initial screening performed on human glioblastoma multiform (GBM) cell lines (GL-15, U251), on murine glioma cells line (C6) and on normal glial cells. Of the compounds tested, the new pyrrolo[1,2a]azepinone, [ethyl (3-oxo-1,2-diphenyl-6,7,8,9-tetrahydro-3H-pyrrolo[1,2a]azepin-9a(5H)-yl)acetate] or (Compound-13) exhibited selective cytotoxic effects on GBM-temozolomide resistant cells. Compound-13 exerted dose-dependent cytotoxic activity by promoting arrest of cells in the G0/G1 phase of the cell cycle in the first 24 h. The apoptotic effect observed was in a time-dependent manner. Anti-migratory effect promoted by the treatment with compound-13 was also observed. Moreover, healthy mixed glial cell cultures from rat brain exhibited no cytotoxicity effect upon exposure to compound-13. Thus, the present study paves the way for the use of compound-13 as novel antitumor scaffold candidate for glioma cell therapy.

Indexed as

AnimalsAntineoplastic AgentsApoptosisAzabicyclo CompoundsBrain NeoplasmsCell CycleCell MovementCells, CulturedCell SurvivalDrug DesignDrug Resistance, NeoplasmGlioblastomaHumansRats, WistarTemozolomideWound HealingAntineoplastic AgentsAzabicyclo CompoundsTemozolomideAnti-tumor agentAzabicyclic compoundsChemoresistanceFormal aza-cyclo additionsGlioblastoma cells

Identifiers

PMID31838735
OpenAlexW2996116338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.